Surgery during chemotherapy and at relapse of ovarian cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Berek, J S ^a   Trope C ^b   Vergote, I ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Palliative secondary surgery; Second look surgery; Secondary interval cytoreductive surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; LAPAROSCOPIC SURGERY; OVARY CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; RELAPSE; REOPERATION; SECOND LOOK SURGERY;

EID: 0032909438     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31477-0     Document Type: Conference Paper

References (56)

1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-4.
2. Griffiths CT, Parker LM, Fuller AJ. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 235-40.
3. Delgado G, Oram DH, Petrilli ES. Stage III Epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984; 18: 293-8.
4. Vogl S, Pagano M, Kaplan B et al. Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer 1983; 51: 2024-30.
5. Pohl R, Dallenback-Hellweg G, Plugge T, Czernobilsky B. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gyneacol Oncol 1984; 2: 160-9.
6. Piver MS, Lele SB, Marchetti DL et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983-9.
7. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence free interval and survival in small-volume stage III epithelial ovarian cancer; a Gynecologic Oncologic Group Study. Gynecol Oncol 1992; 47: 159-66.
8. Hoskins W, Rubin S. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213-21.
9. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-9.
10. Schwartz PE, Smith JP. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124-30.
11. Berek JS, Hacker NF, Lagasse LD et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983; 61: 189-93.
12. Vogl SE, Seltzer V, and Calanog A et al. "Second-effort" surgical resection for bulky ovarian cancer. Cancer 1984; 54: 2220-5.
13. Lippman SM, Alberts DS, Slymen DJ et al. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988; 61: 2571-7.
14. Eisenhauer EA, Vermorken J, Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: an analysis of 704 patients. Ann Oncol 1997; 8: 963-8.
15. Morris M, Gershenson DM, Wharton JT. Secondary ovarian cancer: non-responders to first-line therapy. Gynecol Oncol 1989; 33: 1-5.
16. Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol 1990; 39: 135-8.
17. Morris M, Gershenson DM, Wharton JT et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34: 334-8.
18. Michel G, Zarca D, Castaigne D, Prade M. Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989; 15: 201-4.
19. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990; 38: 203-9.
20. Segna RA, Dottino PR, Mandelli JP et al. Secondary surgical cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993; 11: 434-9.
21. Bristow RE, Lagasse L, Karlan B. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 1996; 78: 2049-62.
22. Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma, Gynecol Oncol 1989; 34: 365-71.
23. Podratz KC, Schray MF, Wieand HS et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 9-24.
24. Potter ME, Hatch KD, Soong SJ et al. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 1992; 44: 3-9.
25. Markman M, Rothman R, Hakes T et al. Second-line cisplatin therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 191; 9: 389-93.
26. Vaccarello L, Rubin SC, Vlamis V et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995; 57: 62-5.
27. Sharp F, Blackett AD, Leake RE, Berek JS. Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum in Ovarian Cancer, May 4-7, 1995, Glasgow, UK. Int J Gynecol Cancer 1995; 5: 449-58.
28. Raju KS, McKinna JA, Barker GH et al. Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol 1982; 144: 650-4.
29. Luesley D, Lawton F, Blackledge G, Kelly K et al. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599-603.
30. Dauplat J, Ferriere JP, Gorbinet M et al. Second-look laparotomy in managing epithelial ovarian carcinoma. Cancer 1986; 57: 1627 (Abstr).
31. Burke JW, Morris M. Secondary cytoreductive operations. pp. 301-312. In Rubin SC, Sutton GP (eds): Ovarian Cancer. McGraw-Hill, New York 1993.
32. Segna RA, Dottino PR, Mandeli JP et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993; 11: 434-9.
33. Rubin SC, Lewis JJ. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988; 8: 75-91.
34. Podratz KC, Kinney WK. Second-look operation in ovarian cancer. Cancer 1993; 71 (Suppl 4): S1551-8.
35. Ng LW, Rubin SC, Hoskins WJ et al. Aggressive chemosurgical debulking in patients with advanced ovarian cancer Gynecol Oncol 1990; 38: 358-63.
36. Lawton F, Luesley D, Redman C et al. Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer. J Surg Oncol 1990; 45: 14-9.
37. Wils J, Blijham G, Naus A et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986; 4: 1068-73.
38. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-34.
39. Berek JS. Interval debulking of epithelial ovarian cancer: an interim measure, N Eng J Med 1995; 332: 675-7.
40. NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273: 491-7.
41. Lawton FG, Redman CW, Luesley DM, Chan KK, Blacklegde G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced unresected epithelial ovarian cancer. Obstet Gynecol 1989; 73: 61-5.
42. Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer. Gynecol Oncol 1991; 42: 146-50.
43. Schwartz PE, Cambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994; 53: 33-7.
44. Surwit E, Childers J, Atlas M, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 356-61.
45. Berek JS, Griffiths CT, Leventhal JM. Laparoscopy for second-look evaluation in ovarian cancer. Obstet Gynecol 1981; 58: 192-8.
46. Berek JS, Hacker NF. Laparoscopy in the management of patients with ovarian carcinoma. In DiSaia P, ed: The Treatment of Ovarian Cancer. London, WB Saunders, 1983, pp 213-22.
47. Krebs HB, Goplerud DR. The role of intestinal intubation in obstruction of the small intestine due to carcinoma of the ovary. Surg Gynecol Obstet 1984; 158: 467-71.
48. Clarke-Pearson D. Chin NO, DeLong ER et al. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol 1987; 26: 11-8.
49. Lund B, Hansen M, Lundvall F et al. Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet 1989; 169: 213-8.
50. Tunca JC, Buchler DA, Mack EA et al. The management in ovarian-cancer-caused bowel obstruction. Gynecol Oncol 1981; 186-92.
51. Castaldo TW, Petrilli ES, Ballon SC, Lagasse LD. Intestinal operations in patients with ovarian carcinoma. Am J Obstet Gynecol 1981; 139: 80-4.
52. Clarke-Pearson D, DeLong ER, Chin N et al. Intestinal Obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg 1988; 123: 42-5.
53. Rubin SC, Hoskins WJ, Benjamin I, Lewis JJ. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989; 34: 16-9.
54. Fernandes JR, Seymour RJ, Suissa S. Bowel obstruction in patients with ovarian cancer: a search for prognostic factors. Am J Obstet Gynecol 1988; 158: 244-9.
55. Malone JJ, Koonce T, Larson DM et al. Palliation of small bowel obstruction by percutaneous gastrostomy in patient with progressive ovarian carcinoma. Obstet Gynecol 1985; 65: 568-72.
56. Baines M. Oliver DJ, Carter RL. Medical Management of intestinal obstruction in patients with advanced malignant disease. Lancet 1985; 2: 990-3.